Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Deal Watch

    - PMLiVE

    WHO urges US to ‘reconsider’ withdrawal from global health organisation

    President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

    - PMLiVE

    Honoring Educational Partners at ACG

    The recent ACG conference was an opportunity for members of the Medscape team to shine a light on their educational partners and honor them for their exceptional work.On October 21,...

    Medscape Education

    International NASH Day 2023

    Shari Dermer, PhD of Medscape Education, hosted Michael Betel, Founder and President of Fatty Liver Alliance, in an engaging conversation around the importance of NASH awareness, diagnosis, and prognosis. Listen...

    Medscape Education

    - PMLiVE

    How the WHO hepatitis strategy measures up in the field

    With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

    Avalere Health

    - PMLiVE

    Future of MHRA uncertain amid Brexit-fuelled shake up

    Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions

    - PMLiVE

    MHRA outlines two-year delivery plan with ‘patient first’ focus

    New delivery plan also outlines strategy for UK regulatory body following Brexit

    - PMLiVE

    Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

    The two companies first announced their NASH collaboration in 2019

    - PMLiVE

    The Brexit clock is counting down and time is running out

    What businesses need to know about post-Brexit immigration

    Podcast

    Living With Chronic Illness (Series one)

    Inizio

    - PMLiVE

    Merck enters agreement with Hanmi for investigational NASH drug

    Licensing agreement includes $10m upfront payment

    - PMLiVE

    Genfit scraps phase 3 trial of experimental NASH drug

    Drug failed to meet primary endpoint in interim analysis

    - PMLiVE

    Zydus Cadila scores first ever NASH approval, in India

    Drug has already been approved for diabetes related conditions

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links